Drug Details
| General Information of the Drug (ID: DR1750) | ||||
|---|---|---|---|---|
| Name |
MK2206
|
|||
| Synonyms |
1032350-13-2; MK-2206 dihydrochloride; MK-2206 2HCl; MK2206; MK-2206 HCl salt; UNII-Q34I3E28IO; MK 2206; 8-(4-(1-Aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride; 8-[4-(1-AMINOCYCLOBUTYL)PHENYL]-9-PHENYL-1,2,4-TRIAZOLO[3,4-F][1,6]NAPHTHYRIDIN-3(2H)-ONE DIHYDROCHLORIDE; Q34I3E28IO; C25H21N5O; MK 2206 2HCl; AHU377 calcium salt; PubChem22473; 1032349-77-1; MK 2206 dihydrochloride; C25H21N5O.HCl; cc-295; C25H21N5O.2HCl; SCHEMBL17100521; EX-A259; SYN1162; AOB87741; ABP000407; MFCD14584463; s1078; AKOS015966903; CCG-264809; MK-2206/MK2206; PB19401; 1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-, hydrochloride (1:2); 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochl; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochloride; AC-28437; AK172013; AS-16298; FT-0672430; SW202557-3; X7427; Z1978; W-5580; J-000912; J-519356; Q27286944; (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester; 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt; 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H,3H-[1,2,4]triazolo[3,4-f]1,6-naphthyridin-3-one hydrochloride
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Nasopharyngeal cancer [ICD-11: 2B6B] | Phase 2 | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C25H23Cl2N5O
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N.Cl.Cl
|
|||
| InChI |
1S/C25H21N5O.2ClH/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31;;/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31);2*1H
|
|||
| InChIKey |
HWUHTJIKQZZBRA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1032350-13-2
|
|||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Bufalin | Bufo gargarizans | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | NCI-H929 | CVCL_1600 | Plasma cell myeloma | Homo sapiens | ||
| U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | |||
| LP-1 | CVCL_0012 | Plasma cell myeloma | Homo sapiens | |||
| RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | |||
| Experimental
Result(s) |
MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Anoctamin-1 | Molecule Info | [2] | |
| Protein kinase B alpha (AKT1) | Molecule Info | [2] | ||
| Protein kinase B beta (AKT2) | Molecule Info | [2] | ||
| Protein kinase B gamma (AKT3) | Molecule Info | [2] | ||
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | ErbB signaling pathway | |||
| 3 | Ras signaling pathway | |||
| 4 | Rap1 signaling pathway | |||
| 5 | cGMP-PKG signaling pathway | |||
| 6 | cAMP signaling pathway | |||
| 7 | Chemokine signaling pathway | |||
| 8 | HIF-1 signaling pathway | |||
| 9 | FoxO signaling pathway | |||
| 10 | Sphingolipid signaling pathway | |||
| 11 | mTOR signaling pathway | |||
| 12 | PI3K-Akt signaling pathway | |||
| 13 | AMPK signaling pathway | |||
| 14 | Apoptosis | |||
| 15 | Adrenergic signaling in cardiomyocytes | |||
| 16 | VEGF signaling pathway | |||
| 17 | Osteoclast differentiation | |||
| 18 | Focal adhesion | |||
| 19 | Tight junction | |||
| 20 | Signaling pathways regulating pluripotency of stem cells | |||
| 21 | Platelet activation | |||
| 22 | Toll-like receptor signaling pathway | |||
| 23 | Jak-STAT signaling pathway | |||
| 24 | T cell receptor signaling pathway | |||
| 25 | B cell receptor signaling pathway | |||
| 26 | Fc epsilon RI signaling pathway | |||
| 27 | Fc gamma R-mediated phagocytosis | |||
| 28 | TNF signaling pathway | |||
| 29 | Neurotrophin signaling pathway | |||
| 30 | Cholinergic synapse | |||
| 31 | Dopaminergic synapse | |||
| 32 | Insulin signaling pathway | |||
| 33 | Progesterone-mediated oocyte maturation | |||
| 34 | Estrogen signaling pathway | |||
| 35 | Prolactin signaling pathway | |||
| 36 | Thyroid hormone signaling pathway | |||
| 37 | Adipocytokine signaling pathway | |||
| 38 | Glucagon signaling pathway | |||
| 39 | Regulation of lipolysis in adipocytes | |||
| 40 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 41 | Carbohydrate digestion and absorption | |||
| 42 | Chagas disease (American trypanosomiasis) | |||
| 43 | Toxoplasmosis | |||
| 44 | Tuberculosis | |||
| 45 | Hepatitis C | |||
| 46 | Hepatitis B | |||
| 47 | Measles | |||
| 48 | Influenza A | |||
| 49 | HTLV-I infection | |||
| 50 | Epstein-Barr virus infection | |||
| 51 | Pathways in cancer | |||
| 52 | Proteoglycans in cancer | |||
| 53 | Colorectal cancer | |||
| 54 | Renal cell carcinoma | |||
| 55 | Pancreatic cancer | |||
| 56 | Endometrial cancer | |||
| 57 | Glioma | |||
| 58 | Prostate cancer | |||
| 59 | Melanoma | |||
| 60 | Chronic myeloid leukemia | |||
| 61 | Acute myeloid leukemia | |||
| 62 | Small cell lung cancer | |||
| 63 | Non-small cell lung cancer | |||
| 64 | Central carbon metabolism in cancer | |||
| 65 | Choline metabolism in cancer | |||
| NetPath Pathway | TSH Signaling Pathway | Click to Show/Hide | ||
| 2 | IL2 Signaling Pathway | |||
| Panther Pathway | Angiogenesis | Click to Show/Hide | ||
| 2 | Apoptosis signaling pathway | |||
| 3 | EGF receptor signaling pathway | |||
| 4 | Endothelin signaling pathway | |||
| 5 | FGF signaling pathway | |||
| 6 | Huntington disease | |||
| 7 | Hypoxia response via HIF activation | |||
| 8 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 9 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
| 10 | Interleukin signaling pathway | |||
| 11 | PI3 kinase pathway | |||
| 12 | T cell activation | |||
| 13 | VEGF signaling pathway | |||
| 14 | p53 pathway | |||
| 15 | Ras Pathway | |||
| 16 | p53 pathway by glucose deprivation | |||
| 17 | p53 pathway feedback loops 2 | |||
| 18 | CCKR signaling map ST | |||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
| 2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
| 3 | Fc Epsilon Receptor I Signaling in Mast Cells | |||
| 4 | Insulin Signalling | |||
| 5 | Leucine Stimulation on Insulin Signaling | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
| 2 | Fc-epsilon receptor I signaling in mast cells | |||
| 3 | Endothelins | |||
| 4 | BCR signaling pathway | |||
| 5 | LPA receptor mediated events | |||
| 6 | Insulin Pathway | |||
| 7 | IL4-mediated signaling events | |||
| 8 | TCR signaling in naï | |||
| 9 | ||||
| 10 | Plasma membrane estrogen receptor signaling | |||
| 11 | CD40/CD40L signaling | |||
| 12 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
| 13 | Signaling events mediated by PTP1B | |||
| 14 | S1P3 pathway | |||
| 15 | Coregulation of Androgen receptor activity | |||
| 16 | Reelin signaling pathway | |||
| 17 | Integrin-linked kinase signaling | |||
| 18 | TCR signaling in naï | |||
| 19 | ||||
| 20 | Angiopoietin receptor Tie2-mediated signaling | |||
| 21 | FAS (CD95) signaling pathway | |||
| 22 | Thromboxane A2 receptor signaling | |||
| 23 | Regulation of Telomerase | |||
| 24 | FOXA2 and FOXA3 transcription factor networks | |||
| 25 | Glucocorticoid receptor regulatory network | |||
| 26 | mTOR signaling pathway | |||
| 27 | CXCR4-mediated signaling events | |||
| 28 | IGF1 pathway | |||
| 29 | FoxO family signaling | |||
| 30 | IL2 signaling events mediated by PI3K | |||
| 31 | Ceramide signaling pathway | |||
| 32 | p75(NTR)-mediated signaling | |||
| 33 | E-cadherin signaling in the nascent adherens junction | |||
| 34 | amb2 Integrin signaling | |||
| 35 | Integrins in angiogenesis | |||
| 36 | IFN-gamma pathway | |||
| 37 | ErbB1 downstream signaling | |||
| 38 | ErbB2/ErbB3 signaling events | |||
| 39 | IL6-mediated signaling events | |||
| 40 | E-cadherin signaling in keratinocytes | |||
| 41 | Nephrin/Neph1 signaling in the kidney podocyte | |||
| 42 | Retinoic acid receptors-mediated signaling | |||
| 43 | IL8- and CXCR2-mediated signaling events | |||
| 44 | Signaling events mediated by the Hedgehog family | |||
| 45 | Nongenotropic Androgen signaling | |||
| 46 | Hedgehog signaling events mediated by Gli proteins | |||
| 47 | Caspase Cascade in Apoptosis | |||
| 48 | CXCR3-mediated signaling events | |||
| 49 | VEGFR1 specific signals | |||
| 50 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| 51 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
| 52 | a6b1 and a6b4 Integrin signaling | |||
| 53 | Aurora A signaling | |||
| 54 | Insulin-mediated glucose transport | |||
| 55 | Class I PI3K signaling events mediated by Akt | |||
| 56 | IL8- and CXCR1-mediated signaling events | |||
| 57 | HIF-1-alpha transcription factor network | |||
| 58 | p53 pathway | |||
| 59 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
| 60 | VEGFR3 signaling in lymphatic endothelium | |||
| 61 | FGF signaling pathway | |||
| Reactome | Activation of BAD and translocation to mitochondria | Click to Show/Hide | ||
| 2 | GPVI-mediated activation cascade | |||
| 3 | PIP3 activates AKT signaling | |||
| 4 | Translocation of GLUT4 to the plasma membrane | |||
| 5 | Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |||
| 6 | AKT phosphorylates targets in the cytosol | |||
| 7 | AKT phosphorylates targets in the nucleus | |||
| 8 | Negative regulation of the PI3K/AKT network | |||
| 9 | eNOS activation | |||
| 10 | AKT-mediated inactivation of FOXO1A | |||
| 11 | Integrin alphaIIb beta3 signaling | |||
| 12 | Deactivation of the beta-catenin transactivating complex | |||
| 13 | CD28 dependent PI3K/Akt signaling | |||
| 14 | CTLA4 inhibitory signaling | |||
| 15 | G beta:gamma signalling through PI3Kgamma | |||
| 16 | KSRP (KHSRP) binds and destabilizes mRNA | |||
| 17 | VEGFR2 mediated vascular permeability | |||
| 18 | TP53 Regulates Metabolic Genes | |||
| 19 | Constitutive Signaling by AKT1 E17K in Cancer | |||
| 20 | Activation of AKT2 | |||
| WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
| 2 | DNA Damage Response (only ATM dependent) | |||
| 3 | TCR Signaling Pathway | |||
| 4 | Notch Signaling Pathway | |||
| 5 | EPO Receptor Signaling | |||
| 6 | IL-2 Signaling Pathway | |||
| 7 | Insulin Signaling | |||
| 8 | Endochondral Ossification | |||
| 9 | EGF/EGFR Signaling Pathway | |||
| 10 | IL-4 Signaling Pathway | |||
| 11 | TGF beta Signaling Pathway | |||
| 12 | IL-6 signaling pathway | |||
| 13 | Wnt Signaling Pathway Netpath | |||
| 14 | Copper homeostasis | |||
| 15 | Extracellular vesicle-mediated signaling in recipient cells | |||
| 16 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
| 17 | IL-3 Signaling Pathway | |||
| 18 | Cardiac Hypertrophic Response | |||
| 19 | Translocation of GLUT4 to the Plasma Membrane | |||
| 20 | Regulation of mRNA Stability by Proteins that Bind AU-rich Elements | |||
| 21 | PIP3 activates AKT signaling | |||
| 22 | Signal Transduction of S1P Receptor | |||
| 23 | T-Cell Receptor and Co-stimulatory Signaling | |||
| 24 | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| 25 | Apoptosis | |||
| 26 | Alpha 6 Beta 4 signaling pathway | |||
| 27 | BDNF signaling pathway | |||
| 28 | Integrated Pancreatic Cancer Pathway | |||
| 29 | Oncostatin M Signaling Pathway | |||
| 30 | Corticotropin-releasing hormone | |||
| 31 | Interleukin-11 Signaling Pathway | |||
| 32 | AGE/RAGE pathway | |||
| 33 | TNF alpha Signaling Pathway | |||
| 34 | B Cell Receptor Signaling Pathway | |||
| 35 | Prostate Cancer | |||
| 36 | Signaling Pathways in Glioblastoma | |||
| 37 | TSLP Signaling Pathway | |||
| 38 | IL17 signaling pathway | |||
| 39 | IL-7 Signaling Pathway | |||
| 40 | Regulation of Microtubule Cytoskeleton | |||
| 41 | TWEAK Signaling Pathway | |||
| 42 | FSH signaling pathway | |||
| 43 | Leptin signaling pathway | |||
| 44 | TSH signaling pathway | |||
| 45 | RANKL/RANK Signaling Pathway | |||
| 46 | Integrated Breast Cancer Pathway | |||
| 47 | SREBP signalling | |||
| 48 | Integrated Cancer pathway | |||
| 49 | IL-1 signaling pathway | |||
| 50 | Metabolism of nitric oxide | |||
| 51 | Integrin-mediated Cell Adhesion | |||
| 52 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
| 53 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 54 | Angiogenesis | |||
| 55 | TOR Signaling | |||
| 56 | Regulation of toll-like receptor signaling pathway | |||
| 57 | AMPK Signaling | |||
| 58 | Androgen receptor signaling pathway | |||
| 59 | IL-5 Signaling Pathway | |||